Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
Jul 3 ABBV AbbVie Q2 IPR&D expenses to lower EPS by $0.52
Jul 3 ABBV Company News for Jul 3, 2024
Jul 3 ABBV AbbVie: A Hold Again (Rating Downgrade)
Jul 2 INO INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Jul 2 VRTX Vertex’s cystic fibrosis drug gets FDA priority review
Jul 2 VRTX Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Jul 2 ABBV With 72% ownership, AbbVie Inc. (NYSE:ABBV) boasts of strong institutional backing
Jul 2 ABBV AbbVie to Host Second-Quarter 2024 Earnings Conference Call
Jul 1 VRTX Vertex to Announce Second Quarter 2024 Financial Results on August 1
Jul 1 ABBV 2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
Jul 1 VRTX Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Jul 1 ABBV AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Jul 1 ABBV AbbVie names Robert A. Michael to CEO role
Jul 1 INO Inovio Pharmaceuticals added to Russell 2000 index effective July 1
Jul 1 ABBV Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
Jul 1 INO INOVIO Added to Russell 2000® Index Effective July 1, 2024
Jul 1 BNTC Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
Jul 1 ABBV 3 Magnificent Stocks Retirees Can Buy and Hold Forever
Jul 1 ABBV 10 clinical trials to watch in the second half of 2024
Jun 29 ABBV How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth?
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags